Uncategorized

As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door

Published

on

Despite the recent emergence of a new drug class, schizophrenia remains one of the most challenging neuropsychiatric diseases to treat—and Cobenfy’s first steps into the market indicate there is still room to grow.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version